



---

Ladies and Gentlemen,

Below I present a summary of the most important events and achievements of the Genomtec S.A. team in H1 2024.

In April and May 2024, we successfully carried out a capital increase transaction, as a result of which over PLN 10 million was added to Genomtec's accounts. This gives us the opportunity to continue business activities during a stage where the company does not generate significant revenues in accordance with our business model of focusing on innovation and R&D.

It was particularly important to inject cash resources in order to commit to our latest OncoSNAAT project. The PLN 21 million FENG grant which we signed an agreement for in December 2023 required co-financing with our own payments, so it was absolutely crucial for us to secure the funds in a timely manner. I am happy to report that the share issue was carried out without a significant discount to the market price. Due to our increasing presence at international scientific and industry forums, we have met with greater interest from investors from outside Poland than in previous years, and during the spring issue, foreign investors joined the shareholding - for the first time on a larger scale and for the first time through an investment agreement.

Our presence at international scientific conferences has been gaining significant momentum over the past year. During this period, we participated in numerous industry and investor conferences: BIO International Convention

(San Diego, USA), ECCMID (Barcelona, Spain), European Economic Congress (Katowice, Poland), German Spring Conference (Frankfurt, Germany), and ASCO (Chicago, USA), where we presented scientific achievements, established industry and business relationships, and advanced the M&A process conducted by Clairfield Partners.

At the same time, our Supervisory Board is becoming international and is strengthened with industry experience brought by Mr. Gualtiero Garlasco and Dr. Trevor Hawkins.

The comparative study of the Genomtec ID platform conducted in France and Poland aims to expand the clinical validation of RP5-plex for the new IVDR regulations. As a reminder, the diagnostic parameters and clinical validation of the RP5-plex has already been established during IVDD certification in May 2022. This registration was based on the analysis of 120 throat swab samples, allowing for the absence of false-positive and false-negative results, as well as the high resistance of the product to interfering substances such as drugs, hygiene products or food that may be found in the biological sample. Recruitment in France and Poland takes longer than expected due to the lower incidence of respiratory infections, especially in the area of atypical bacteria. With the April 2024 vote of the European Parliament, the European Commission this year postponed the deadline for the obligation to register in-vitro diagnostic medical devices belonging to group B in the IVDR regime from May 2025 to the end of 2029. The current registration thus protects us for another 5 years. This means that the quick completion of the clinical trial is no longer a priority and in the upcoming respiratory season we will continue to collect samples through classic patient recruitment.

On the R&D front, in addition to new area related to oncology, we are conducting tests and work related to further improvement of the Genomtec ID platform. Laboratory work carried out by the team has already led to, among other things, a significant reduction in amplification time. For example, the time to obtain a result for Influenza A/B, was less than 10 minutes. The matrix concentration is only 50 copies of the virus per reaction in many repetitions. These are times unheard of in existing PCR tests and our great success, which once validated will become a differentiated competitive advantage.

We also organized a webinar with the participation of respected scientists on the prospects for oncological diagnostics in the context of the technology developed by Genomtec. The meeting is available at the link <https://www.youtube.com/watch?v=RHbedGaSde4&t=11s>

At this point, I would like to thank everyone who contributed to the development of Genomtec and at the same time I would like to thank our current shareholders and investors who joined the shareholding in the spring of 2024 for their trust.

Thank you for your trust.

Miron Tokarski,

President of the Management Board, co-founder and shareholder of Genomtec S.A.